Table 2 Baseline characteristics
RIPC+RIPostC (n = 60) | Control (n = 60) | P value | |
|---|---|---|---|
Demographics | |||
Age (years) | 46.5 ± 16.2 | 47.1 ± 12.4 | 0.983 |
Male | 45 (75.0%) | 44 (73.3%) | 0.835 |
BMI | 21.6 ± 3.7 | 21.4 ± 3.2 | 0.990 |
Distribution of primary diseases | |||
Coronary heart diseases | 10(16.7%) | 9(15%) | 0.803 |
Cardiomyopathy | |||
Dilated cardiomyopathy | 29(48.3%) | 32(53.3%) | 0.584 |
Hypertrophic cardiomyopathy | 5(8.3%) | 7(11.7%) | 0.543 |
Restrictive cardiomyopathy | 3(5%) | 3(5%) | 1 |
ARVC | 6(10%) | 3(5%) | 0.488 |
Alcoholic cardiomyopathy | 1(1.7%) | 1(1.7%) | 1 |
Peripartum cardiomyopathy | 0 | 1(1.7%) | 1 |
Noncompaction of ventricular myocardium | 2(3.3%) | 1(1.7%) | 1 |
Valvular heart disease | 3(5.0%) | 2(3.3%) | 1 |
Behcet disease | 1(1.7%) | 0 | 1 |
Myocarditis | 0 | 1(1.7%) | 1 |
Risk factors and comorbidities | |||
Hypertension | 7 (11.7%) | 6 (10%) | 0.518 |
Diabetes mellitus | 13 (21.7%) | 10 (16.7%) | 0.487 |
Hypercholesterolemia | 12 (20%) | 12 (20%) | 1 |
Previous myocardial infarction | 6 (10%) | 4 (6.7%) | 0.509 |
Previous stroke | 6 (10%) | 6 (10%) | 1 |
Previous atrial fibrillation | 20 (33.3%) | 20 (33.3%) | 1 |
Previous cardiac surgery | 6 (10%) | 8 (13.3%) | 0.570 |
Cardiac status | |||
Left-ventricular ejection fraction (%) | |||
> 55% | 4(6.7%) | 3(5%) | 1 |
35–55% | 8(13.3%) | 12(20%) | 0.327 |
< 35% | 47(78.3%) | 45(75%) | 0.666 |
Previous pacemaker | 18(30%) | 16(26.7%) | 0.685 |
Preoperative medication | |||
Warfarin | 8(13.3%) | 12(20%) | 0.327 |
β blocker | 50(83.3%) | 52(86.7%) | 0.609 |
Lipid-lowering agent | 3(5%) | 8(13.3%) | 0.114 |
ACE inhibitors or ARB | 30(50%) | 11(18.3%) | < 0.001 |
Aldosterone receptor blocker | 46(76.7%) | 57(95%) | 0.803 |
Digitalis | 16(26.7%) | 49(81.7%) | < 0.001 |
Nitrates | 5(8.3%) | 12(20%) | 0.670 |
Anti-diabetic drugs | 6(10%) | 8(13.3%) | 0.570 |
Inotropic drugs | 23(38.3%) | 46(76.7%) | < 0.001 |